Recent Finacing
Recent Raise
Talaris develops proprietary allogeneic cell therapy FCR001 to induce immune tolerance in organ transplant recipients and immune-mediated disorders, running a Phase 3 LDKT trial and a Louisville cell‑processing facility.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Talaris Therapeutics.
